As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
Activists with Black Lives Matter, who met privately with Buttigieg in the weeks after police shot and killed Eric Logan, say the 37-year-old mayor brushed off their concerns...2020 Electionsread more
Trump said he "is revoking" a federal waiver that allowed the state to craft its own rules on greenhouse gas emissions from vehicles.Politicsread more
Wall Street economists think the Fed will cut rates by 25 basis points at its September meeting but have differing views about what will happen in the future.Marketsread more
The Business Roundtable said its members forecast that growth this year will clock in at 2.3%, down from last quarter's estimate of 2.6%.Politicsread more
The unspecified action comes after the U.S. accused Iran of carrying out the weekend attacks on critical Saudi oil installations.Politicsread more
Drone and missile debris recovered by investigators at the Saudi Aramco attack site is proof of Iranian culpability, a Saudi defense ministry representative told media on...World Politicsread more
Four Wall Street firms downgraded FedEx after the company's poor earnings report.Marketsread more
Some worry the regulators will squander an opportunity to crack down on potentially monopolistic behavior due to their own infighting.Technologyread more
FedEx CEO Fred Smith is "basically implying that we're going to import" a global slowdown," says CNBC's Jim Cramer.Investingread more
Oil prices retreated after President Donald Trump said he ordered the Treasury Department to "substantially increase" sanctions on Iran.Energy Commoditiesread more
Emerging markets still offer room for growth, the chief executive of Roche told CNBC on Thursday after the Swiss pharmaceutical group posted an 8 percent increase in third-quarter sales.
Severin Schwan said he was "very pleased" with the performance of the group over the last nine months after the group's sales increase was helped by growing momentum of its new breast cancer drugs.
"A big contribution of the increase is due to emerging markets as we penetrate the markets with our medicines," he told CNBC Europe's "Squawk Box". He added that penetration rates in some emerging markets were still relatively low and these offered further potential.
Roche -- the world's largest maker of cancer drugs -- confirmed its forecast of rising sales and profit for this year after quarterly sales rose to 11.57 billion Swiss francs ($12.63 billion), compared with the average analyst forecast of 11.54 billion francs in a Reuters poll.
Speaking to CNBC from Basel, Switzerland, where the company is based, Schwan said the company was "also extending our portfolio in important areas" and had numerous products in the pipeline.
"We have a strong position in oncology and we will continue to develop important and innovative medicines in this area. However, we are also active in neuroscience and inflamation," he said.
He would not comment on rumors that Roche and fellow Swiss multinational pharmaceutical company Novartis could merge but said in broader terms, Roche did not like "mega mergers."